Management of Ethambutol‑Induced Optic Toxicity in People Living with HIV on Anti‑TB Therapy

Immediate Discontinuation and Substitution

• Stop ethambutol at once when any visual symptom (decreased acuity, scotomata, color‑vision loss) is reported, and never rechallenge the drug because the toxicity may be irreversible【1】.
• If the patient is also receiving linezolid, discontinue both agents immediately when optic neuritis occurs; linezolid may be re‑introduced after vision normalizes, but ethambutol should not be re‑started【1】.
• Replace ethambutol with an alternative anti‑TB drug to keep at least five effective agents in the regimen【1】.

Diagnostic Confirmation of Ethambutol Toxicity

• Perform formal visual‑acuity testing with a Snellen chart to document the degree of impairment【2】.
• Conduct red‑green color‑discrimination testing (e.g., Ishihara plates) as a hallmark of ethambutol‑related optic neuropathy【3】.
• Use finger‑perimetry (visual‑field assessment) to detect scotomata【2】.
• Recognize that ethambutol‑induced optic neuropathy presents as optic or retro‑bulbar neuritis and is dose‑dependent【1】.

Regimen Modification After Ethambutol Discontinuation

• First‑line replacement: add a fluoroquinolone (moxifloxacin 400 mg daily or levofloxacin) when the Mycobacterium tuberculosis isolate is drug‑susceptible and the patient is not already on a fluoroquinolone【1】.
• Alternative replacement: use streptomycin (if renal function permits and the drug is available) with appropriate renal monitoring【2】.
• For rifampin‑resistant or MDR‑TB: ensure inclusion of Group A drugs such as bedaquiline and linezolid together with a fluoroquinolone【4】.

HIV‑Specific Drug‑Interaction Management

• Rifampin markedly lowers protease‑inhibitor concentrations via CYP3A induction, an effect that can persist up to two weeks after rifampin cessation【2】.
• Preferred approach: discontinue protease inhibitors and switch to an efavirenz‑based antiretroviral regimen for the duration of TB therapy【2】.
• If protease inhibitors must be retained, either omit rifampin and extend TB treatment to 18 months, or substitute rifabutin (reduced dose) and use indinavir as the protease inhibitor【2】.

Timing of Antiretroviral Therapy Initiation

• For patients not yet on ART, initiate antiretroviral therapy at the end of the 2‑month intensive phase of TB treatment (or after TB completion) to lessen pill burden, overlapping toxicities, and improve adherence【5】.

Baseline and Ongoing Monitoring to Prevent Toxicity

• Baseline: obtain visual‑acuity and color‑discrimination tests before starting ethambutol, and verify that the patient understands the need to stop the drug and report any visual change【2】【3】.
• Renal assessment: check renal function before ethambutol initiation; avoid or substantially reduce the dose in patients with creatinine clearance < 70 mL/min or end‑stage renal disease【3】.
• Monthly follow‑up: perform visual‑acuity and color‑discrimination testing each month, especially for patients on higher doses, treatment > 2 months, or with renal insufficiency【1】.
• Actively inquire about blurred vision, scotomata, or color‑vision changes at every visit【3】.
• For young children or patients with communication barriers, educate family members to observe and report visual changes, using ethambutol cautiously in these groups【2】.

Prognosis and Reversibility

• Ethambutol‑induced optic toxicity is generally reversible if identified promptly and the drug is stopped or the dose is reduced【1】.
• Because toxicity is dose‑dependent, delayed recognition can result in permanent visual impairment【1】.

Common Pitfalls to Avoid

• Do not continue ethambutol while “monitoring closely” after suspected toxicity; immediate discontinuation is required【3】.
• Do not prescribe ethambutol to patients who cannot reliably report visual symptoms unless a caregiver can monitor for changes【2】.
• Do not omit replacement of ethambutol without adding another effective drug, as this risks treatment failure or acquired resistance【1】.
• Do not overlook renal dosing adjustments; failure to do so increases the risk of optic toxicity【3】.
• Do not ignore the rifampin–protease‑inhibitor interaction in PLHIV, because sub‑therapeutic protease‑inhibitor levels can lead to HIV treatment failure【5】.

Management of Neurologic Adverse Events in Patients Receiving Anti‑Tubercular Therapy

Immediate Actions

• Discontinue all anti‑tubercular drugs promptly when a patient on therapy develops new slurred speech (dysarthria), because this may represent a serious neurologic adverse event that requires urgent evaluation. 6

Evaluation of Drug‑Induced Neurotoxicity

Isoniazid‑related Neuropathy

• Assess for peripheral neuropathy symptoms (e.g., paresthesias, weakness) and, when available, measure serum vitamin B6 levels to identify isoniazid‑induced neuropathy. 6

Ethambutol‑related Optic/Neurologic Toxicity

• Perform formal visual‑acuity testing and visual‑field assessment to detect ethambutol‑induced optic neuropathy and rare neurologic effects. 6

Rifampicin‑related Interactions

• Review all concurrent medications for potential interactions with rifampicin that could produce central nervous system effects. 6

Management When Toxicity Is Confirmed

• Do not re‑introduce the offending anti‑tubercular drug if severe neurotoxicity (e.g., ethambutol optic neuropathy or marked isoniazid neuropathy) is confirmed. 6
• Replace the offending agent with an alternative such as streptomycin (if not contraindicated) or a fluoroquinolone to complete the regimen. 7
• Add pyridoxine 50–100 mg daily when isoniazid‑induced neuropathy is suspected, even if pyridoxine was not previously prescribed. 6
• If rifampicin or pyrazinamide must be omitted because of toxicity, extend the total treatment duration to 9–12 months. 7

Ongoing Surveillance

• Conduct monthly visual‑acuity checks while ethambutol is continued to monitor for emerging optic toxicity. 6

HIV‑Related Considerations

• Test all patients with neurologic deterioration on anti‑tubercular therapy for HIV infection, as HIV‑positive individuals have higher rates of CNS tuberculosis, paradoxical reactions, and drug toxicity. 8
• Delay initiation of antiretroviral therapy by 8 weeks in patients with CNS tuberculosis to reduce the risk of severe immune‑reconstitution inflammatory syndrome, unless the CD4 count is < 50 cells/µL. 8

Management of HIV/TB Co‑infection When Ethambutol‑Induced Optic Toxicity Occurs

1. Characteristics and Risk Factors of Ethambutol Optic Toxicity

• Ethambutol‑induced optic neuropathy typically presents as optic or retro‑bulbar neuritis and is dose‑dependent; the risk increases with daily dosing, treatment duration longer than 2 months, or impaired renal function. 9

2. HIV Antiretroviral Therapy (ART) Management

2.1 When to Maintain the Current Tenofovir + Lamivudine + Dolutegravir Regimen

• The tenofovir/lamivudine/dolutegravir combination should not be altered unless there is documented HIV virologic failure (HIV‑RNA > 200 copies/mL) or a toxicity directly attributable to the ART agents. 10
• This regimen is regarded as a preferred first‑line HIV therapy with high efficacy and tolerability; ethambutol‑related optic toxicity does not constitute a reason to change ART. 10

2.2 Monitoring HIV Virologic Suppression After TB‑Drug Modifications

• After any modification of the TB regimen (e.g., discontinuing ethambutol), HIV viral load should be re‑checked 1 month later to confirm continued virologic suppression. 10
• If the HIV‑RNA remains < 50 copies/mL, the existing tenofovir/lamivudine/dolutegravir regimen can be continued unchanged. 10

2.3 Drug‑Interaction Considerations with Rifampin

• Tenofovir, lamivudine, and dolutegravir have no clinically significant interaction with rifampin; therefore, no ART dose adjustment is required when rifampin is part of the TB regimen. 10

2.4 Explicit Recommendation Against ART Modification for Ethambutol Toxicity

• Clinicians should avoid altering the tenofovir/lamivudine/dolutegravir regimen solely because of ethambutol‑induced optic toxicity, as the antiretroviral drugs are not implicated and the regimen remains highly effective. 10

Ethambutol‑Induced Optic Toxicity: Evidence‑Based Key Points

Fundoscopic and Clinical Manifestations

Visual Function Testing

Dose‑ and Duration‑Dependent Risk

Monitoring and Management Recommendations

Differential Diagnosis in People Living with HIV (PLHIV)

Management of Ethambutol‑Induced Optic Toxicity

Immediate Actions When Toxicity Is Suspected

• Discontinue ethambutol permanently at the first sign of any visual symptom (decreased acuity, red‑green color loss, or scotomata) because toxicity may be irreversible and rechallenge is contraindicated. [14][15]
• Stop ethambutol immediately when a patient reports blurred vision, difficulty distinguishing colors (especially red‑green), or visual‑field defects. [14][15]

Diagnostic Confirmation

• Red‑green color discrimination testing (e.g., Ishihara plates) is a hallmark finding of ethambutol‑induced optic neuropathy. 16

Regimen Modification After Discontinuation

• Replace ethambutol with streptomycin (when renal function permits) and adjust the dose according to renal status, with appropriate monitoring. [14][15]
• If ethambutol is omitted and pyrazinamide cannot be used or tolerated, extend the total treatment duration to nine months. 17

Baseline Screening and Patient Education (Pre‑Treatment)

• Perform baseline visual‑acuity testing with a Snellen chart and document the patient’s ability to notice and report visual changes. [14][15]
• Verify renal function before prescribing ethambutol; avoid the drug in renal failure or substantially reduce the dose with therapeutic drug monitoring if dialysis is required. [14][15]
• Educate the patient (and caregivers for children or individuals with communication barriers) to stop ethambutol immediately and notify the physician if any visual symptoms develop. [14][15]
• Inform the patient’s primary care physician of the need for immediate discontinuation of ethambutol upon visual symptom onset. [14][15]

Special Populations and Precautions

Children and Patients with Communication Barriers

• Use ethambutol cautiously in young children and individuals who cannot reliably report visual symptoms; provide education to parents or caregivers to observe and report any visual changes. [14][15]

Renal Impairment

• Avoid ethambutol or substantially reduce the dose in patients with creatinine clearance < 70 mL/min or end‑stage renal disease. [14][15]
• When ethambutol must be used in renal failure, monitor serum drug concentrations and adjust dosing accordingly. [14][15]

Safety Checks and Common Pitfalls

• Do not prescribe ethambutol to patients who cannot reliably report visual symptoms unless a caregiver is able to monitor for changes. [14][15]
• Do not overlook renal dosing adjustments; failure to reduce the dose in renal impairment markedly increases the risk of optic toxicity. [14][15]